Prognostic significance of international prognostic index(IPI) in peripheral T-cell lymphoma, not otherwise specified

( views:, downloads: )
Author:
WANG Yi-nan(Department of Oncology, Hebei Tangshan People's Hospital, Tangshan 063001, China)
LI Hong-min()
MA Shou-dong(Department of Oncology, Hebei Tangshan People's Hospital, Tangshan 063001, China)
ZHAO Yu(Department of Oncology, Hebei Tangshan People's Hospital, Tangshan 063001, China)
LIU Wei-dong(Department of Oncology, Hebei Tangshan People's Hospital, Tangshan 063001, China)
YUE Hai-shu(Department of Oncology, Hebei Tangshan People's Hospital, Tangshan 063001, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 18, Issue 10, 2009
DOI:
10.3760/cma.j.issn.1009-9921.2009.10.008
Key Word:
T-cell lymphoma non otherwise specified; International prognostic index; Prognosis

Abstract: Objective To evaluate the international prognostic index (IPI) in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Methods From May 2005 to May 2008, 75 patients of PTCL--NOS were reviewed. All the patients were diagnosed again by immunohistochemical staining. According to IPI, they were divided into four groups:low risk (0-1), intermediate-low(2), intermediate-high(3), high risk (4-5), then the difference of treatment effectiveness and prognosis among them were analysed. Results IPI scoring of 75 patients were classified as low risk , 10 (13.3%); as intermediate-low, 14 (18.7%); as intermediate-high, 28 (37.3 %); as high risk, 23 (30.7%). There was a significant difference in complete remission rates with first line treatment(X2=16.677,P=0.001), and overall survival rates (P=0.0000) among four groups. Median survival time among 4 groups were 36+, 29.00, 17.00, 10.00 months. 1-year OS were 100.00 %, 89.05 %, 64.24 %, 15.73 %; 2-year OS were: 75.00 %, 53.01%, 34.42 %, 2.00 % respectively. Multivariate analysis showed that both complete remission rates of first line treatment(P=0.002) and IPI(P = 0.049) were independent prognostic factor for PTCL-NOS, while single index of IPI was not. Conclusion At a certain extent, IPI model was able to predict response of treatment effective and prognosis in PTCL-NOS.

  • [1]Rodriguez-Abreu D,Filho VB,Zucca E.Peripheral T-cell lymphomas,unspecified (or not otherwise specified):a review.Hematol Oncol,2008,26:8-20.
  • [2]A predictive model for aggressive non-Hodgkin's lymphoma.The International non-Hodgkin's lymphoma prognostic factors project.N Engl J Med,1993,329:987-994.
  • [3]于燕霞,石远凯,何小慧,等.非特异性外周T细胞淋巴瘤的临床特征与治疗结果分析.中华医学杂志,2007,87:2714-2716.
  • [4]岑洪,胡晓桦,周文献,等.163例外周T细胞淋巴瘤-非特指型患者的临床特征及预后分析.中国肿瘤临床,2007,34:982-985.
  • [5]Lossos IS,Morgensztem D.Prognostic hiomarkers in diffuse large B-cell lymphoma.J Clin Oncol,2006,24:995-1007.
  • [6]窦红菊,胡钧培,唐勇,等.弥漫大B细胞淋巴瘤患者VEGF表达与IPI的关系.白血病·淋巴瘤,2009,18:155-157.
  • [7]Went P,Agostinelli C,Gallamini A,et al.Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologicprognostic score.J Clin Oncol,2006,24:2472-2479.
  • [8]Lee Y,Uhm JE,Lee HY,et al.Clinical features and prognostic factors of patients with "peripheral T cell lymphoma,unspecified".Ann Hematol,2009,88:111-119.
  • [9]郑文,朱军,谢玉泉,等.外周T细胞淋巴瘤临床分析.中华内科杂志,2007,46:60-61.
  • [10]Reimer P,Ruediger T,Weissinger F,et al.Different outcome for angioimmunoblastic T-cell lymphoma (All,) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation.Blood,(ASH Annual Meeting Abstracts) 2006,108:Abstract 5431.
  • [11]Gallamini A,Stelitano C,Calvi R,et al.Peripheral T-cell lymphorna unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study.Blood,2004,103:2474-2479.
  • [12]Vose M.International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project:poor outcome by prognostic indices and lack of efficacy with anthracyclines.Blood,(ASH Annual Meeting Abstracts) 2005,106:Abstract 811.
  • [13]彭玉龙,黄慧强,周中梅,等.外周T细胞淋巴瘤-非特指型(TCL-U)117例长期临床随访结果分析.中国癌症杂志,2006,16:132-135.
  • [14]黄慧强,潘战和,林旭滨,等.IPI评分对中国外周T细胞淋巴瘤预后判断价值的探讨.第四届中国肿瘤学术大会论文集,天津:中国抗癌协会,2006:839.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn